Interestingly, recently published data reported increased survival rates for palliative CCA receiving standard of care chemotherapy if a PD-L1 inhibitor is added [38] while we confirmed clinically relevant CD274 (PD-L1) deregulation in MUC16 (+) patients by companion IHC diagnostics of PD-L1. The gene discussed is CD274; the disease is cholangiocarcinoma.